Skip navigation
Watchlist Sponsored By :


Current DateTime: 03:59:01 01 Dec 2009
LinksList Documentid: 24355697
  • The Cost of True Love

      In the popular holiday song "The 12 Days of Christmas," the cost of gifts - from the 12 drummers drumming to a partridge in a pear tree - is quite pricey.

  • Runway Angels

      The superbowl of fashion shows, models walk down the runway at the 2009 Victoria's Secret Show.

  • Smartphone Guide

      Here's a need-to-know guide to nine devices, based on features, price, network and platform.

FEATURED QUIZZES


Current DateTime: 03:59:01 01 Dec 2009
LinksList Documentid: 33793611
  • Test Your Google IQ

      How much do you know about the most popular search engine in the world? Take the following quiz and find out.

  • A Healthier & Wealthier You

      Take the following quiz and find out how much you know about the impact of obesity on the health of the U.S. economy.

  • How Well Do You Know Your Bird?

      Let's talk turkey. Test your turkey knowledge and perhaps pick up a bit of trivia to trot out at your holiday meal.


Current DateTime: 03:59:01 01 Dec 2009
LinksList Documentid: 24890560
  • Predictions '10

      After a brutal 2009, we're all looking forward to 2010. Here's what our bloggers expect.

  • Holiday Central

      There are plenty of reasons to believe that this Christmas holiday season will not be as bad for retailers as last year.

  • Winterizing Your Portfolio

      If 2009 was the winter of our discontent, will 2010 be a winter wonderland for investors? A lot depends on the recovery—or lack thereof.

powered by digg
By: Reuters | 29 Apr 2008 | 11:20 AM ET
Text Size

U.S. health regulators have rejected a new drug from Merck that was designed to raise the level of HDL, or "good" cholesterol, the company said, sending its shares [MRK  Loading...      ()   ] plunging more than 10 percent.
Merck
AP

The company declined to discuss details in the so-called "not approvable" letter from the Food and Drug Administration.

It would not comment on whether the agency had asked for further data or new clinical trials.

The drug, which was expected to be called Cordaptive, combines long-acting niacin with a new drug that prevents the flushing side effect common to niacin — an uncomfortable sensation of burning in the face and neck that leads many patients to discontinue taking it.

Analysts widely expected the drug to be approved, especially after a committee of European regulators last week recommended it be cleared for sale there.

The rejection was another blow for Merck, whose share price has fallen more than 30 percent this year amid a controversy and debate over the effectiveness of the cholesterol drugs it sells in a joint venture with Schering-Plough [SGP  Loading...      ()   ].

The FDA decision should be a boon to Abbott Laboratories, whose franchise of niacin-based cholesterol drugs would have been in direct competition with Merck's proposed new entry into the lucrative market.

Abbott shares [ABT  Loading...      ()   ] were up more than 2.5 percent following the Merck news.

Deutsche Bank analyst Barbara Ryan called the news a disappointment.

"We expected the drug to get approved," she said. "It's not going to have any impact on the earnings outlook for this year, but certainly as we go out in time they could have had an important contribution from the drug."

Merck said it would meet with the FDA to submit additional information to enable the agency to further evaluate the benefit/risk profile of the drug, which it has gone back to calling MK-0524A after the FDA also rejected the prospective brand name Cordaptive.

"We firmly believe that MK-0524A provides physicians with an important option to manage their patients' cholesterol," Merck's research chief Peter Kim said in a statement.

The company said it did not yet know when a meeting with FDA officials might take place.

In clinical trials, the laropiprant component of the drug demonstrated an ability to significantly reduce the flushing effect of niacin.

It had been hoped the combination would enable patients to tolerate niacin at a dose that provides the most therapeutic benefit.

Despite the setback, Merck reaffirmed the 2008 forecast it issued last week and reiterated confidence in meeting its goal of double-digit annual earnings per share growth through 2010, excluding certain items.

Some analysts believed that Cordaptive and a planned follow-up combination drug that also includes Merck's bad cholesterol lowering Zocor could eventually garner $1 billion to $2 billion in annual sales.

Copyright 2009 Reuters. Click for restrictions.
Tools:
Print EmailAdd This share icon
  • digg share

CNBC HIGHLIGHTS

  • Will the Fed raise rates? Will the dollar continue its slide? CNBC experts weigh in on the year ahead.
  • Lloyd Blankfein
  • Goldman Sachs has forbidden employees from gathering in private holiday parties of 12 or more.
  • Lemonade stand
  • Do you have what it takes to run your own business? Ask yourself these questions.
  • Heavily armed pirates in Somalia have set up a sort of stock exhange to fund their hijackings.
  • Since its launch in 1998, Google has become a primary force on the Internet. How much do you know about the company?
  • typewriter
  • A famed author has written all his work on an old typewriter that is now up for auction. The NYT reports.
ADD COMMENTS
Remaining characters


Current DateTime: 01:30:04 01 Dec 2009
LinksList Documentid: 29778428

Current DateTime: 01:04:12 01 Dec 2009
LinksList Documentid: 29779196

Current DateTime: 10:29:37 01 Dec 2009
LinksList Documentid: 29779199

Current DateTime: 07:24:02 01 Dec 2009
LinksList Documentid: 29779198
  Data is a real-time snapshot  *Data is delayed at least 15 minutes
Global Business and Financial News, Stock Quotes, and Market Data and Analysis

© 2009 CNBC, Inc.  All Rights Reserved.
A Division of NBC Universal
Thomson ReutersThomson Reuters